**Background**
Bacterial infections remain a significant global health challenge, particularly urinary tract infections (UTIs) which can range from uncomplicated cystitis to complex systemic infections. The management of these conditions requires potent antimicrobial agents capable of targeting a wide array of pathogens. DNA gyrase and topoisomerase IV are essential enzymes in bacteria, responsible for managing DNA supercoiling and separating daughter DNA strands during replication. Inhibition of these enzymes leads to the cessation of bacterial cell division and subsequent cell death, making them primary targets for drug development. In this context, we will introduce a broad-spectrum antibiotic – Norfloxacin.
**Definition**
Norfloxacin is a synthetic chemotherapeutic antibacterial agent and a member of the quinolone class that targets DNA gyrase and topoisomerase IV. According to the Norfloxacin description, it is active against both Gram-positive and Gram-negative bacteria.
**In Vitro Studies**
The Norfloxacin biological activity is characterized by its ability to inhibit bacterial proliferation by disrupting essential DNA processes. Beyond its primary antibacterial use, research has explored its effects on various human and animal cell lines. In vitro studies have demonstrated that Norfloxacin exhibits varying degrees of cytotoxicity and antiproliferative activity. For instance, in human A431 cells, the IC50 values for cytotoxicity and proliferation inhibition were reported as 137 μM and 70 μM, respectively. In human MCF7 cells, the compound showed dark toxicity with an IC50 of 13.8 μM and general cytotoxicity with an IC50 of 137 μM. Furthermore, Norfloxacin exhibited an IC50 of 150 μM against human KB cells and 86 μM against NCI-H460 cells. In animal models, it showed cytotoxicity against rat L6 cells with an IC50 of 3.4311 μM and against mouse CT26 cells with an IC50 of 0.33 mM (incubated for 4 hours). Conversely, it showed minimal toxicity toward mouse NIH/3T3 cells (IC50 > 1000 μM) and human PBMC (IC50 > 0.5 mM). For researchers seeking detailed Norfloxacin technical information, these data highlight the compound’s broad biological impact across different cell types. In conclusion, Norfloxacin is a broad-spectrum antibiotic that functions by inhibiting DNA gyrase and topoisomerase IV to prevent bacterial cell division.
Keywords
Norfloxacin, 70458-96-7, MK-0366, MK0366, MK 0366, Bacterial, Endogenous Metabolite, Antibiotic, Inhibitor, inhibitor, inhibit
References
[1] Nelson JM, et al. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis. 2007 Apr 1;44(7):977-80. Epub 2007 Feb 14.
[2] Pade?skaia EN. Norfloxacin: more than 20 years of clinical use, the results and place among fluoroquinolones in modern chemotherapy for infections. Antibiot Khimioter. 2003;48(9):28-36.
[3] Rafalsky V, et al. Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003597.